ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
52 announcements with these filters
Gland Pharma announced a long-term strategic CDMO partnership with Neuland Laboratories to expand its sterile API manufacturing infrastructure at its Visakhapatnam facility.
Gland Pharma Limited submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026, as per SEBI regulations.
Gland Pharma has issued a notice for its 48th Annual General Meeting to be held on August 25, 2026. The meeting agenda includes dividend declaration and director reappointments.
Gland Pharma Limited announced the grant of 16,790 employee stock options to 3 employees under the Gland Pharma Employee Stock Option Scheme 2025.
Gland Pharma received USFDA approval for Sugammadex Injection single-dose vials. The product has been successfully launched via its marketing partner.
Gland Pharma Limited has scheduled a board meeting on August 10, 2026, to consider and approve its unaudited standalone and consolidated financial results.
Gland Pharma shareholders approved the reappointment of Udo Jahannes Vetter and the appointment of William Robert Keller as Independent Directors for five-year terms.
Gland Pharma Limited announced the results of the Postal Ballot, where all proposed resolutions regarding the appointment and remuneration of Independent Directors were passed.
Gland Pharma submitted its quarterly shareholding pattern for the period ending June 30, 2026. This is a routine regulatory disclosure.
Gland Pharma received a ₹7.06 Crore demand and penalty notice from Customs Authorities. The company plans to appeal, citing no material financial impact.
Gland Pharma received a Rs. 7.06 Crore demand from Customs Authority, including IGST and penalties. The company intends to appeal against the order.
Mirae Asset Mutual Fund sold a 0.18% stake in Gland Pharma via open market. Its holding decreased from 5.17% to 4.98%.
Independent Director Mr. Satyanarayana Murthy Chavali resigned due to potential conflict of interest. His departure effective June 15, 2026, ensures governance standards.
Gland Pharma's board approved re-appointment of an independent director, appointed a new independent director, and accepted a resignation. These changes strengthen board governance with experienced pharmaceutical leaders.
Gland Pharma allotted 2,03,259 equity shares following the exercise of employee stock options. This issuance raised approximately ₹1.04 Crore and increased the total paid-up share capital.
Gland Pharma filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms full compliance with SEBI regulations and listing requirements.
Gland Pharma reported record quarterly revenue of INR 17,428M (+22% YoY) for Q4FY26, driven by CDMO growth and the Cenexi turnaround. FY26 adjusted PAT reached INR 10,455M with a 16% margin.
Gland Pharma reports a recovery quarter with consolidated revenue up 7% and a sharp 39% EBITDA jump, primarily driven by Cenexi reaching EBITDA break-even and lower raw material costs.
Gland Pharma reports strong FY26 performance with 14% revenue growth and 50% Adj. PAT growth, driven by US market gains and Cenexi recovery.
Gland Pharma Ltd reported revenue from operations of ₹1,743 Cr (+22.3% YoY) and net profit of ₹366.7 Cr (+96.6% YoY) for Q4 FY26.
Gland Pharma Limited reappointed Ms. Naina Lal Kidwai as Independent Director for five years starting May 2026. The reappointment ensures leadership stability and strong corporate governance.
Gland Pharma Limited announced the successful reappointment of Ms. Naina Lal Kidwai as an Independent Director through postal ballot. Shareholders approved the resolution with requisite majority.